Tumour lysis syndrome
Oncologic metabolic · Metabolic
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Massive tumour cell breakdown (spontaneous or post-chemotherapy) releasing potassium, phosphate and urate — causing hyperkalaemia, hyperphosphataemia, hypocalcaemia and AKI.
Red flags
- Hyperkalaemia with ECG changes
- Oliguric AKI
- Symptomatic hypocalcaemia (tetany/seizure)
- Arrhythmia
Assessment
Differential diagnosis
- Rhabdomyolysis
- AKI (other cause)
- Primary hyperkalaemia
- Sepsis with organ dysfunction
Investigations
- U&E, potassium, phosphate, calcium, urate, LDH
- ECG (hyperkalaemia), VBG
- FBC; identify malignancy/treatment timing
- Cairo-Bishop criteria
Management
- Aggressive IV hydration to maintain urine output
- Treat hyperkalaemia urgently (calcium, insulin-dextrose, salbutamol) — cardiac monitor
- Rasburicase for high urate (or allopurinol for prevention/lower risk)
- Avoid IV calcium for hypocalcaemia unless symptomatic (worsens phosphate precipitation)
- Renal/oncology referral; dialysis for refractory hyperkalaemia or severe AKI
Drugs & doses
IV crystalloid
Rasburicase (or allopurinol)
Hyperkalaemia therapy
Disposition
Admit; HDU/ICU; oncology + renal.
Complications & pitfalls
- Life-threatening hyperkalaemia
- AKI
- Arrhythmia, seizures
Exam pearls
- Hydration + rasburicase are the key prophylaxis and treatment
- Avoid giving calcium for asymptomatic hypocalcaemia (calcium-phosphate precipitation)
- Rasburicase is contraindicated in G6PD deficiency
Hydrate hard, treat hyperkalaemia, lower urate with rasburicase, and involve renal early.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.